Diamonds and Dogs
Chegg (CHGG) chugging along. The online tutoring, textbook and other educational service company is up 9% to a new all-time following better than expected earnings. Chegg easily beat earnings expectations as sales 30% to $95.68 million. The company also raised first quarter and full year guidance. It is fourth time in the last four quarters Chegg has come in above Wall Street expectations. Management said they have entered the year with strong momentum, giving them confidence to raise guidance as they focus on our mission of helping students improve their outcomes.
Gilead (GILD) going the wrong way. The biotech drug maker is down 5% not far from a 52 week low after their new liver disease drug Selonsertib failed in Phase 3 trials. Selonsertib is an investigational drug taken orally that was expected to treat patients with compensated cirrhosis caused by nonalcoholic steatohepatitis, or NASH, a chronic and progressive liver disease characterized by fat accumulation and inflammation in the liver. Gilead remains committed to advancing therapies for patients with advanced fibrosis due to NASH, but the company needs some wins to turn business and the stock around.
Diamonds and Dogs market commentary is a journal of daily observations on anything that happens to be of interest to our author. Obviously, our primary focus is the stock market and world economic events, but for this page we have no defined topics. We want this page to be dedicated to the interests, concerns, and possibly to the financial gain of our clients and friends. All comments contained herein are for informational purposes only, and should not be considered as a solicitation to buy or sell any security. The firm does not guarantee the accuracy or completeness of the information or make any warranties regarding results from it's usage.